343 results about "Lung injury" patented technology

Invented is a method of inhibiting the activity / function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

Lung injury such as pneumothorax now can be diagnosed reliably, portably and quickly. Vibro-acoustic waves are sent through the chest and the resulting wave is measured. By analyzing attenuation characteristics determined by the geometry of the chest structures, a determination can be made of whether the patient's pleural space is healthy, contains air (pneumothorax) or contains fluid (hemothorax).

Invented is a method of inhibiting the activity / function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.

We disclose a new and useful biomarker for acute kidney injury (i.e., AKI), renal ischemia reperfusion injury (i.e., IRI), ischemic acute kidney injury, and / or ischemic acute tubular necrosis (i.e., ATN). The biomarker is GRO-alpha (i.e., CXCL1, chemokine C-X-C ligand 1, GRO1, GROa, MGSA, MGSA alpha, MGSA-a, NAP-3, SCYB1). We detected the biomarker using a QUANTIKINE® human GRO-alpha immunoassay (Cat. No. DGR00, R & D Systems, Minneapolis, Minn.). In addition, we disclose a method of treating lung damage.

Pharmaceutical composition for the treatment of infant respiratory distress syndrome and acute lung injury (including adult respiratory distress syndrome) which contains C1 esterase inhibitor (C1-INH) and lung surfactant which comprises a lung surfactant protein.

A process and a device is presented with an electro-impedance tomography (EIT) system (2), with a computing unit (4) and with a respirator (1) for gentle mechanical lung ventilation especially in case of atelectases following surgical procedures. A first image of the healthy lungs is first recorded prior to anesthetization by means of the EIT system (2) and the total area and / or the spatial distribution of ventilated lung areas are determined from the image values by means of the computing unit (4). Second or additional status images are recorded after assumed lung damage and the total area and / or the spatial distribution of ventilated lung areas are determined. The total areas and / or the spatial distribution of the ventilated lung areas from the first and second or further status images are compared by means of the computing unit (4) and analyzed for the presence of lung areas that have no or reduced ventilation due to atelectases. The information on the presence, the extent and / or the spatial distribution of atelectases is sent by the EIT system (2) to the respirator (1) so that the respiration pressure is increased step by step by the respirator (1) as a function of the status image or the currently determined status images until the current image of the lung status corresponds to the first status image or comes close to it with minimal deviations. The respiration pressure is subsequently reduced again step by step by the respirator (1) until the computing unit (4) detects a reduction of the ventilated lung areas and the respiration pressure is subsequently increased again by means of the respirator (1) to the last value at which no change occurred in the ventilated lung areas.

Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.

Invented is a method of inhibiting the activity / function of PI3 kinases using pyridosulfonamide derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of pyridosulfonamide derivatives.

The invention relates to the field of biology, in particular to MSC (mesenchymal stem cell) injection as well as a preparation and an application thereof. The injection comprises MSCs and a cell cryopreservation solution, wherein the cryopreservation solution comprises components in percentage by volume as follows: 25%-70% of an electrolyte balance solution, 5%-20% of clinical-grade DMSO (dimethyl sulfoxide), 1%-50% of 20% human serum albumin, 1%-10% of hydroxyethyl starch 130 / 0.4 and 5%-20% of triphosadenine-disodium magnesium chloride freeze-drying powder. The injection is free of animal serum, has clear ingredients and good cell cryopreservation effect and is safe and controllable, long-term storage and long-distance transport are facilitated, the survival rate of cells after recovery is higher than 95%, the vitality is high, and the injection can effectively relieve injury and inflammation symptoms of lesion tissue of lungs and promote tissue regeneration of the lungs, so that acute lung injury can be fundamentally and comprehensively treated.

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.

A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.

The present invention is related to azolidinedione-vinyl fused-benzene derivatives of formula (I) for the treatment and / or prophylaxis of autoimmune disorders and / or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries. Formula (I), wherein A, X, Y, Z, R1, R2 and n are as described in the description.

Methods and compositions are provided for the treatment of acute lung injury and pulmonary fibrosis by administering inhibitors of IGF-1R signaling activity.

During lung injury, p53 expression increases, inducing plasminogen activator inhibitor-1 (PAI-1) while inhibiting expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR), resulting in apoptosis of lung epithelial cells (LECs). In the bleomycin lung injury model, p53 and PAI-1 are induced while uPA and uPAR are inhibited. A 20 residue peptide DGIWKASFTTFTVTKYWFYR termed PP-1 (the Cav-1 scaffolding domain) or peptide NYHYLESSMTALYTLGH, termed PP-2, protected LECs from bleomycin-induced apoptosis in vitro and in vivo and prevented subsequent pulmonary fibrosis by attenuating lung epitheilial damage. Pharmaceutical compositions, peptide multimers and deliverable polypeptides comprising the above peptides are dislcosed. The peptides and functional variants, peptide multimers, cell-targeted polyepeptides and pharmaceutical compositions are used in methods for inhibiting apoptosis of injured or damaged lung epithelial cells and for treating acute lung injury and consequent pulmonary fibrosis.

The embodiment of the invention provides a pulmonary ultrasound image analysis method and apparatus, an electronic device and a readable storage medium. The method comprises the following steps: obtaining a pulmonary ultrasound image, then marking the pulmonary ultrasound image based on a pulmonary ultrasound sign, then inputting the marked pulmonary ultrasound image into a pre-trained dense convolutional network model, and analyzing the pulmonary ultrasound image by using the dense convolutional network model to obtain an analysis result of a lung injury degree corresponding to the pulmonaryultrasound image. The obtained pulmonary ultrasound image is analyzed by using the pre-trained dense convolutional network model, the obtained analysis result can reflect the lung injury degree corresponding to the pulmonary ultrasound image, therefore, the purpose of characterizing the lug health condition according to the analysis result is achieved, and the technical problem that the ultrasoundimage cannot be analyzed and processed to study the health state of a patient based on the analysis result in the prior art is solved.

The present invention is related to 2-imino-azolinone-vinyl fused-benzene derivatives of Formula (1) in particular for the treatment and / or prophylaxis of autoimmune disorders and / or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

The invention discloses a pulmonary rehabilitation training system based on respiratory-muscle electrical signal feedback. The pulmonary rehabilitation training system comprises a controller, a magnetic directional valve, a flow sensor and an electrode connected with the controller through an amplifying circuit, wherein the magnetic directional valve and the flow sensor are connected with the controller. One way of the magnetic directional valve is communicated to an airway interface through the flow sensor. The other two ways of the magnetic directional valve are communicated with a pressureproportion regulating valve A and a pressure proportion regulating valve B, and the magnetic directional valve is switched and selected in the two ways. The pressure proportion regulating valve A is connected with a medical positive pressure air source. The pressure proportion regulating valve B is connected with a medical negative pressure air source. The pulmonary rehabilitation training systemis mainly used for a patient difficult in mechanical ventilation weaning, senses the tolerance of the patient in the pulmonary rehabilitation training process, intelligently adjusts the pressure and flow of breathing airflow in the rehabilitation training process, improves interpersonal coordination degree, avoids man-machine counteraction and lung injuries and promotes recuperation of autonomousrespiration ability.

Invented is a method of inhibiting the activity / function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.

The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.

Invented is a method of inhibiting the activity / function of PI3 kinases using naphthyridine derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of naphthyridine derivatives.

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.

A patient is monitored for a medical condition such as acute lung injury (ALl) by operations including: (i) receiving values of a plurality of physiological parameters for the patient; (ii) computing an ALl indicator value based at least on the received values of the plurality of physiological parameters for the patient; and (iii) displaying a representation of the computed ALl indicator value on a display (14, 22). The computing operation (ii) may employ various inference algorithms trained on a training set comprising reference patients to distinguish between reference patients having ALl and reference patients not having ALl, or may employ an aggregation of two or more such inference algorithms. If patients in an ICU are monitored, the display (22) may simultaneously display a diagrammatic representation of each patient including an identification of the patient and a representation of the ALl indicator value for the patient.

Compositions comprising an RNA interference (RNAi) compound complexed to or encapsulated by lipid particles are provided. The lipid particle is a lipid nanoparticle, a liposome or a combination thereof. The lipid particle comprises a cationic lipid, a phospholipid, a sterol or a tocopherol or a derivative thereof, and a conjugated lipid. The invention also provides methods for treating pulmonary diseases or disorders such as pulmonary fibrosis and sarcoidosis using the compositions comprising the RNAi-lipid particles of the invention. The methods comprise administering one or more of the RNAi compositions to the lungs of the patient in need thereof via an inhalation delivery device, for example, a nebulizer, dry powder inhaler, or a metered dose inhaler.

The invention relates to the usage of pirfenidone for treating hepatic injury and necrosis and acute lung injury, more specifically the invention relates to the application of pirfenidone in abatement of symptoms for patients with hepatic injury, necrosis and acute lung injury, and in lowering mortality rate. The invention also provides the medicinal composition for treating hepatic injury, necrosis and acute lung injury.

A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.

The invention discloses an intelligent outflow resistance switching simulation breathing apparatus, which comprises a fan, an air cushioning cavity, an inlet airflow sensor, an airbag, an outlet airflow sensor, an air valve, a pressure sensor and a signal processing and control unit, wherein the signal processing and control unit comprises a signal processing and control circuit and computer-loaded signal processing and control software; and signal transmission is achieved by virtue of an information acquisition card, so that the breathing apparatus is driven and controlled. The breathing apparatus disclosed by the invention can be used for automatically controlling a tidal volume and a ventilation rhythm by automatically adjusting the motion amplitude and the motion rhythm of the valve. In addition, the breathing apparatus is designed with intelligent regulating and control functions such as ventilation supporting strength determination and control function, lung injury ventilation function, apnea automatic handling function and the like, so as to provide appropriate ventilation support strength to patients, reduce related lung injury of the breathing apparatus and guarantee the ventilation safety of the patients on the breathing apparatus.

Methods and compositions comprising antagonists of αvβ6 are provided for the treatment of acute lung injury fibrosis.